MedTrace Logo

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

NCT06014905 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-05-25

No results posted yet for this study

Summary

This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior

Conditions

  • Meningioma

Interventions

DRUG

Hyperpolarized carbon C 13 pyruvate

Given Intravenously (IV)

PROCEDURE

Magnetic Resonance Image (MRI)

Imaging procedure

OTHER

Saline

Given IV

Sponsors & Collaborators

  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)

    collaborator NIH

  • General Electric

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • Javier Villaneuva-Meyer, MD

    lead OTHER

Principal Investigators

  • Javier Villanueva-Meyer, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06014905 on ClinicalTrials.gov